长春高新(000661.SZ)：金赛药业GS3-007a干混悬剂境内生产药品注册临床试验申请获得受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of GS3-007a dry mixed suspension, marking a significant step in the development of this drug [1] Group 1 - The GS3-007a dry mixed suspension is an orally administered small molecule growth hormone secretagogue developed by Jinsai Pharmaceutical [1] - The drug is classified as a Class 1 chemical drug and is intended for the treatment of pediatric growth hormone deficiency (PGHD) caused by endogenous growth hormone deficiency [1]